Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
BörsenkürzelEVOK
Name des UnternehmensEvoke Pharma Inc
IPO-datumSep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeSep 25
Addresse420 Stevens Avenue
StadtSOLANA BEACH
BörseLondon Stock Exchange
LandUnited States of America
Postleitzahl92075
Telefon18583451494
Websitehttps://evokepharma.com/
BörsenkürzelEVOK
IPO-datumSep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten